The ophthalmic devices market was valued at USD 20.5 billion in 2025 and is estimated at USD 21.9 billion in 2026. Grand View Research projects it will reach USD 39.1 billion by 2033, growing at a CAGR of 8.6% from 2026 to 2033. North America led the global ophthalmic devices market with a 29.5% revenue share in 2025, while Asia Pacific is expected to be the fastest-growing region.

Market Size and Growth Projections

Between 2025 and 2033, the ophthalmic devices market is on course to add roughly USD 18.6 billion in revenue, nearly doubling in eight years. This revenue is largely generated by diagnostic and surgical equipment such as scanners, cameras and laser systems. Sustained growth at 8.6% a year therefore points to steady, repeat investment by providers rather than a short-lived spike.

Several forces explain the climb. The rising prevalence of glaucoma, cataracts, diabetic retinopathy and vitreoretinal disorders forms the base. The World Health Organization (WHO) reports that nearly 422 million people worldwide live with diabetes, a condition closely tied to diabetes-related blindness. The National Institute on Aging expects the geriatric population to reach around 72 million by 2030, and older adults are more prone to age-related eye disorders. Increased screen time is also pushing more people toward eye examinations.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Policy adds momentum. In May 2024, the WHO launched its SPECS 2030 programme to help countries achieve a 40% increase in access to appropriate spectacles. Technology improvements in lasers, diagnostics and surgical techniques have also made it easier to manage cataracts, macular degeneration, glaucoma and dry eye disease.

A useful way to read the regional picture is by what pulls demand in each place. North America’s lead comes from an ageing population, chronic conditions such as diabetic retinopathy, newer reimbursement models and a stringent regulatory framework. Europe benefits from developed healthcare infrastructure and favourable reimbursement, and the European Commission has allocated around USD 5.66 billion (EUR 5.3 billion) through EU4Health for 2021 to 2027.

Download a free sample report or claim your copy of this full market intelligence report

Asia Pacific’s growth leans more on access and policy:

• India’s National Programme for Prevention and Control of Blindness promotes affordable diagnostic devices.
• China’s growing product approvals widen the availability of advanced equipment.
• Japan’s demographics, with over 10% of people aged 80 and above in 2023, create steady demand for precise diagnostics.

In the Middle East, Saudi Arabia’s large-scale AI-based diabetic tele-retinopathy screening project shows how national programmes can create demand for imaging technology.

Key Market Segments

Product: Imaging Leads

Optical coherence tomography (OCT) held the largest product share at 23.2% in 2025. OCT produces high-resolution cross-sectional and three-dimensional images, and it is widely used to diagnose glaucoma, age-related macular degeneration and diabetic eye disease. Its pairing with artificial intelligence is expected to lift adoption. In October 2024, Carl Zeiss expanded its offerings with AI digital tools, including ZEISS VisioGen for refractive patient communication and clinic workflows.

Ophthalmoscopes are projected to grow at 8.9% over the forecast period. In January 2025, Norlase received FDA 510(k) clearance and CE Mark approval for its LYNX Pattern Scanning Laser Indirect Ophthalmoscope, a battery-powered, untethered laser solution.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Application: Cataract Volume, Refractive Speed

Cataract is the largest application segment, with a 41.4% revenue share in 2024. The WHO attributes nearly 51% of global blindness cases to cataracts, which keeps surgical and diagnostic demand high. Refractive disorders are expected to be the fastest-growing application. The WHO estimates that approximately 2.2 billion people worldwide have near- or far-sighted vision impairment. Instruments such as phoropters and retinoscopes are preferred to detect and correct these errors.

End-Use: Clinics and Research Labs

Hospitals and eye clinics hold the largest end-use share and are expected to stay ahead. Mergers and acquisitions between clinics and hospitals are likely to generate fresh installations, and many clinics are building dedicated diagnostic departments. In June 2023, for example, Eye-Q installed a customised LASIK machine at its Rewari facility in India.

Academic and research laboratories are also expected to grow significantly. Institutions such as the Johns Hopkins Wilmer Eye Institute receive major funding from the National Eye Institute. Labs like these run clinical trials, validate technology and work with industry partners, which shortens innovation cycles.

Taken together, the segment data shows a diagnostics-first ophthalmic devices market. Imaging leads by product, surgical volume leads by application, and refractive care is the fastest-moving frontier.

Major Industry Players

Grand View Research identifies the following ten companies as the leading names in the ophthalmic devices market:

• Johnson & Johnson Vision Care
• Alcon Vision LLC
• Carl Zeiss Meditec AG
• Bausch & Lomb Incorporated
• Essilor International S.A
• Ziemer Ophthalmic Systems Ltd
• Nidek Co. Ltd
• TOPCON Corporation
• Haag-Streit Group
• Glaukos Corporation

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Competition in this space rewards adaptability. Large companies lean on brand strength and distribution, while smaller players grow through specialisation. Investment in R&D, especially in intraocular lenses, laser systems and diagnostics, helps firms defend their share.

Recent moves show how this plays out. Carl Zeiss Meditec acquired 100% of the Dutch Ophthalmic Research Center from Eurazeo in December 2023, blending its products with digitally connected vision care solutions. In July 2024, Alcon received FDA approval for UNIPURE C3F8 Ophthalmic Gas for retinal detachment. Johnson & Johnson Vision presented its Elita laser correction platform in the U.S. in August 2023, and Bausch + Lomb launched INFUSE Multifocal daily disposable lenses in June 2023. Mergers and acquisitions have an especially high impact in intraocular lenses and surgical devices, while regulators such as the FDA and the MHRA keep approval processes transparent and build trust in new products.

What to Watch Next

The ophthalmic devices market is moving toward connected, AI-supported and more portable care. In June 2024, C3 Med-Tech received Rs. 2 crores (USD 0.24 million) to develop AI-enabled portable ophthalmic devices for telemedicine. Substitutes such as advanced contact lenses and ocular drug delivery systems will keep competing for some conditions. Even so, the ophthalmic devices market has a firm base in ageing populations, rising diabetes and expanding access to eye care. For manufacturers, investors and providers, the path from USD 21.9 billion in 2026 to USD 39.1 billion in 2033 runs through imaging, refractive solutions and emerging regions.

Check Out Our Dedicated Business Offerings –

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today